EARNEST Partners’s Sarepta Therapeutics SRPT Stock Holding History

EARNEST Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-31	Closed	-$3.76K	–	974
2023 Q3	$3.76K	Hold	31	–	–	﹤0.01%	872
2023 Q2	$3.55K	Hold	31	–	–	﹤0.01%	885
2023 Q1	$4.27K	Hold	31	–	–	﹤0.01%	833
2022 Q4	$4.02K	Hold	31	–	–	﹤0.01%	847
2022 Q3	$3K	Hold	31	–	–	﹤0.01%	918
2022 Q2	$2K	Hold	31	–	–	﹤0.01%	1028
2022 Q1	$2K	Hold	31	–	–	﹤0.01%	1046
2021 Q4	$3K	Hold	31	–	–	﹤0.01%	982
2021 Q3	$3K	Hold	31	–	–	﹤0.01%	982
2021 Q2	$2K	Hold	31	–	–	﹤0.01%	1056
2021 Q1	$2K	Hold	31	–	–	﹤0.01%	1060
2020 Q4	$5K	Hold	31	–	–	﹤0.01%	836
2020 Q3	$4K	Hold	31	–	–	﹤0.01%	843
2020 Q2	$5K	Hold	31	–	–	﹤0.01%	743
2020 Q1	$3K	Hold	31	–	–	﹤0.01%	839
2019 Q4	$4K	Hold	31	–	–	﹤0.01%	866
2019 Q3	$2K	Hold	31	–	–	﹤0.01%	1011
2019 Q2	$5K	Hold	31	–	–	﹤0.01%	779
2019 Q1	$4K	Hold	31	–	–	﹤0.01%	856
2018 Q4	$3K	Hold	31	–	–	﹤0.01%	900
2018 Q3	$5K	Hold	31	–	–	﹤0.01%	797
2018 Q2	$4K	Buy	+31	New	+$2.92K	﹤0.01%	871

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EARNEST Partners's SRPT Position: Q4 2023 in Review

EARNEST Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 31 shares — an estimated $3.76K sold.

EARNEST Partners first reported a position in SRPT in Q2 2018 and held it in 22 quarters. The position peaked at $5K in Q4 2020. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

EARNEST Partners reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 31 Sarepta Therapeutics shares in Q4 2023, an estimated $3.76K.
EARNEST Partners first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 22 quarters.
EARNEST Partners's Sarepta Therapeutics position peaked at $5K in Q4 2020.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.